NCT02222870View on ClinicalTrials.gov

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

June 30, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® Quadrivalent Influenza Vaccine, No Preservative

0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)

BIOLOGICAL

Fluzone® Quadrivalent Influenza Vaccine, No Preservative

0.5 mL, Intramuscular (2014-2015 formulation)

Trial Locations (2)

40040

Bardstown

84121

Salt Lake City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02222870 - Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine | Biotech Hunter | Biotech Hunter